国邦医药集团股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为规范国邦医药集团股份有限公司（以下简称"公司"）的内幕信 息管理，加强内幕信息保密工作，防范内幕交易及内幕信息泄露，根据《中华 人民共和国证券法》（以下简称《证券法》）《上市公司监管指引第 5 号——上 市公司内幕信息知情人登记管理制度》《国邦医药集团股份有限公司信息披露 管理制度》（以下简称《公司信息披露管理制度》）的有关规定，制定本制度。 （三）公司订立重要合同、提供重大担保或者从事关联交易，可能对公司 的资产、负债、权益和经营成果产生重要影响； （四）公司发生重大债务和未能清偿到期重大债务的违约情况，或者发生 大额赔偿责任； （五）公司发生重大亏损或者重大损失，或者放弃债权或者财产超过上年 末净资产的 10%； 第二条 本制度适用于国邦医药集团股份有限公司内幕信息及其知情人的 管理事宜。本制度未规定的，参照《公司信息披露管理制度》的相关规定。 第三条 公司董事、高级管理人员及公司各部门和子公司都应配合做好内 幕信息知情人登记报备工作，不得进行内幕交易或配合他人操纵证券交易价格。 公司及各部门、各子公司需按照本制度规定，做好本部 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-041 一、回购股份的基本情况 国邦医药集团股份有限公司（以下简称"公司"）于 2025 年 3 月 10 日召开第二 届董事会第十一次会议，审议通过了《关于以集中竞价交易方式回购股份方案的 议案》，同意公司使用自有资金及自筹资金以集中竞价交易方式回购公司股份用 于后续实施股权激励或员工持股计划，回购价格不超过人民币 25 元/股（含），回 购资金总额不低于人民币 1 亿元且不超过人民币 2 亿元，回购期限为 2025 年 3 月 11 日至 2026 年 3 月 10 日。具体内容详见公司分别于 2025 年 3 月 11 日、2025 年 3 月 15 日在上海证券交易所网站（www.sse.com.cn）披露的《国邦医药关于以集 中竞价方式回购股份方案的公告》（公告编号：2025-005）、《国邦医药关于以集 中竞价交易方式回购股份的回购报告书》（公告编号：2025-006）。 二、回购股份的进展情况 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》的相关规定，现将公司回购股份的进展情况公告如下： ...

Group 1 - The core point of the news is that Guobang Pharmaceutical has completed a share transfer agreement with a state-owned operating company, involving approximately 38.31 million shares, which accounts for 6.85% of the company's total shares [1] - The shareholders involved in the transfer are Shiqihui, Hong Dehui, and Shi Qingde, who are transferring their shares of approximately 27.45 million, 10.23 million, and 630,000 shares respectively [1] - The share transfer was confirmed by the Shanghai Stock Exchange on September 23, 2025, and the transfer registration was completed on September 29, 2025 [1] Group 2 - For the year 2024, Guobang Pharmaceutical's revenue composition is as follows: the pharmaceutical segment accounts for 64.87%, the animal health products segment accounts for 34.24%, and other businesses account for 0.88% [2] - As of the latest report, Guobang Pharmaceutical has a market capitalization of 12.4 billion yuan [3]

证券代码：605507 证券简称：国邦医药 公告编号：2025-040 国邦医药集团股份有限公司 关于公司股东协议转让股份过户完成的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 8 月 20 日，国邦医药集团股份有限公司（以下简称"公司"、"国 邦医药"）持股 5%以上股东潍坊仕琦汇股权投资合伙企业（有限合伙）（以下简 称"仕琦汇"）、潍坊洪德辉股权投资合伙企业（有限合伙）（以下简称"洪德辉"） 及绍兴世庆德企业管理咨询合伙企业（有限合伙）（以下简称"世庆德"）与浙江 省国有资本运营有限公司（以下简称"国有运营公司"）签署了《股份转让协议》， 仕琦汇、洪德辉及世庆德拟通过协议转让的方式将其持有的国邦医药 27,445,600 股（占公司股份总数的 4.91%）、10,227,103 股（占公司股份总数的 1.83%）及 633,600 股（占公司股份总数的 0.11%）无限售流通股通过协议转让 的方式转让给国有运营公司，转让股份合计占公司股份总数的 6.85%。 本次协议转让交易 ...

Market Overview - The Shanghai Composite Index closed at 3813.56 points, with a decline of 1.16% [1] - The total trading volume of A-shares reached 23956.82 billion yuan [1] Technical Analysis - A total of 16 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sichuang Medical (300078) with a distance of -0.91% - Nanmo Biology (688265) with a distance of -0.80% - Shandong Weida (002026) with a distance of -0.75% [1] Individual Stock Performance - Sichuang Medical (300078) saw a decrease of 2.81% with a trading turnover rate of 3.15% [1] - Nanmo Biology (688265) decreased by 0.16% with a turnover rate of 1.39% [1] - Shandong Weida (002026) declined by 2.93% with a turnover rate of 2.90% [1] - Qingda Environmental (688501) dropped by 3.86% with a turnover rate of 1.84% [1] - Pulit (002324) fell by 2.62% with a turnover rate of 2.03% [1] - Other notable declines include: - Meili (000815) down by 4.03% - Hezhong (002383) down by 6.95% [1]

Group 1 - The company Guobang Pharmaceutical (SH 605507) announced on September 1 that it has repurchased approximately 5.38 million shares through centralized bidding, accounting for 0.96% of the total share capital, with a total expenditure of about 103 million yuan [1][1][1] - The highest and lowest prices for the repurchased shares were 19.88 yuan/share and 18.61 yuan/share, respectively [1][1][1] - As of the report, Guobang Pharmaceutical has a market capitalization of 12.9 billion yuan [1][1][1] Group 2 - For the fiscal year 2024, the revenue composition of Guobang Pharmaceutical is as follows: the pharmaceutical segment accounts for 64.87%, the animal health products segment accounts for 34.24%, and other businesses account for 0.88% [1][1][1]

格隆汇9月1日丨国邦医药(605507.SH)公布，截至2025年8月31日，公司通过集中竞价交易方式累计回购 股份5,375,274股，已回购股份占公司总股本的比例为0.96%，成交的最高价为19.88元/股，最低价为 18.61元/股，已支付的总金额为1.03亿元（不含交易费用）。 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-039 二、回购股份的进展情况 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》的相关规定，现将公司回购股份的进展情况公告如下： 截至 2025 年 8 月 31 日，公司通过集中竞价交易方式累计回购股份 5,375,274 股，已回购股份占公司总股本的比例为 0.96%，成交的最高价为 19.88 元/股，最低 价为 18.61 元/股，已支付的总金额为 102,600,172.21 元（不含交易费用）。 上述回购事项符合相关法律法规的规定及公司回购股份方案的要求。 三、其他事项 国邦医药集团股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/11 | | --- | --- | | 回购方案实施期限 | 2025/3/11~2026/3/10 | | 预计回购金额 | 1亿元~2亿元 | | 回购用途 | □减少注册资本 √用于 ...

Core Viewpoint - Guobang Pharmaceutical (605507.SH) has introduced local state-owned capital by transferring 38.31 million shares, representing 6.85% of the total share capital, to Zhejiang State-owned Capital Operation Co., Ltd. for a total consideration of 791 million yuan [2][4]. Shareholder Changes - The transfer involves three shareholders: Weifang Shiqihui Equity Investment Partnership, Weifang Hongdehui Equity Investment Partnership, and Shaoxing Shiqingde Enterprise Management Consulting Partnership, who will reduce their holdings to 4.04%, 0.79%, and 0.07% respectively after the transaction [5]. - Following the transaction, the state-owned operation company will become the fourth largest shareholder of Guobang Pharmaceutical [5]. Strategic Intent - The transfer aims to introduce a strategic investor to support the optimization of the company's equity structure and enhance its strategic development [2][5]. - The state-owned operation company plans to support Guobang Pharmaceutical's comprehensive development in the pharmaceutical field and improve its risk resistance capabilities [2][5]. Financial Performance - For the first half of 2025, Guobang Pharmaceutical reported a revenue of 3.026 billion yuan, a year-on-year increase of 4.63%, and a net profit of 456 million yuan, up 12.6% [2][7]. - The company has maintained a strong market position in its core product areas, with significant growth in its pharmaceutical raw materials and animal health businesses [8]. R&D and Market Position - Guobang Pharmaceutical is recognized as one of the largest suppliers of macrolide and quinolone raw materials globally, with a comprehensive product layout in the domestic animal health raw materials sector [7][8]. - The company has invested 97.43 million yuan in R&D in the first half of 2025, reflecting a 4.8% increase, and holds a total of 216 patents [8]. Dividend Policy - Since its listing in 2021, Guobang Pharmaceutical has distributed a total of 1.228 billion yuan in dividends and has implemented two share buyback plans totaling over 200 million yuan [3][8].

Core Viewpoint - The announcement details the transfer of shares from major shareholders of Guobang Pharmaceutical to Zhejiang State-owned Capital Operation Co., aiming to introduce a strategic investor to support the company's development in the pharmaceutical industry [1][2]. Summary by Sections 1. Overview of the Share Transfer Agreement - The share transfer involves three major shareholders: Weifang Shiqihui Equity Investment Partnership, Weifang Hongdehui Equity Investment Partnership, and Shaoxing Shiqingde Enterprise Management Partnership, transferring a total of 27,445,600 shares, representing 4.91% of the company's total share capital, to Zhejiang State-owned Capital Operation Co. at a price of 20.66 yuan per share, totaling approximately 567 million yuan [3][4]. 2. Strategic Cooperation Post-Transfer - After the share transfer, Zhejiang State-owned Capital Operation Co. plans to support Guobang Pharmaceutical's comprehensive development in the pharmaceutical sector, focusing on areas such as industry chain collaboration, new business cultivation, and capital operations [2][12]. 3. Shareholding Changes - Following the transfer, the shareholding structure will change, with Weifang Shiqihui holding 22,575,596 shares (4.04%), Weifang Hongdehui holding 4,441,550 shares (0.79%), and Shaoxing Shiqingde holding 393,875 shares (0.07%) [5][6]. 4. Compliance and Approval Process - The share transfer is subject to compliance confirmation by the Shanghai Stock Exchange and must be registered with the China Securities Depository and Clearing Corporation [6][13]. 5. Impact on Company Operations - The transfer will not change the controlling shareholder or actual controller of the company, ensuring stability in operations and decision-making processes [12][13]. The introduction of a strategic investor is expected to enhance the company's core competitiveness and resource synergy [12][13]. 6. Commitment from the New Shareholder - Zhejiang State-owned Capital Operation Co. has committed not to reduce its shareholding within six months following the transfer [2][14].